Name | calpain inhibitor ii |
---|---|
Synonyms |
N-Acetyl-L-leucyl-N-[(2S)-4-(methylsulfanyl)-1-oxo-2-butanyl]-L-leucinamide
N-AC-LEU-LEU-METHIONINAL AC-LEU-LEU-L-METHIONINAL L-Leucinamide, N-acetyl-L-leucyl-N-[(1S)-1-formyl-3-(methylthio)propyl]- Ac-Leu-Leu-Met-al N-Acetyl-L-leucyl-N-[(2S)-4-(methylsulfanyl)-1-oxobutan-2-yl]-L-leucinamide ALLM AC-LEU-LEU-MET-ALDEHYDE AC-LEU-LEU-METHIONINAL AC-LEU-LEU-MET-CHO N-ACETYL-LEU-LEU-MET-CHO MFCD00065506 AC-LLM-CHO |
Description | ALLM (Calpain inhibitor II) is a potent inhibitor of calpain and cathepsin proteases. ALLM inhibits neuronal cell death and improves chronic neurological function after spinal cord injury (SCI)[1][2]. |
---|---|
Related Catalog | |
In Vivo | ALLM (Calpain inhibitor II) (0.5 mg/kg) is injected every 24 h for 5 days after SCI and inhibits the activation of calpain but not that of caspase 3. ALLM prevents this neuronal cell death[2]. ALLM (0.05-2.5 mg/kg; i.p.; every 24 h for 1 week) reduces motor disturbances after spinal cord injury (SCI)[2]. Animal Model: Adult male Wistar rats (280-300g) (spinal cord injury model)[2] Dosage: 0.05, 0.5, and 2.5 mg/kg Administration: Intraperitoneally; every 24 h for 1 week Result: Showed significantly better motor function. |
References |
Density | 1.1±0.1 g/cm3 |
---|---|
Boiling Point | 676.5±55.0 °C at 760 mmHg |
Molecular Formula | C19H35N3O4S |
Molecular Weight | 401.564 |
Flash Point | 362.9±31.5 °C |
Exact Mass | 401.234833 |
PSA | 129.67000 |
LogP | 2.64 |
Vapour Pressure | 0.0±2.1 mmHg at 25°C |
Index of Refraction | 1.496 |
Storage condition | −20°C |
Water Solubility | Very slightly soluble (0.52 g/L) (25 ºC) |
Hazard Codes | Xi |
---|---|
Safety Phrases | S22-S24/25 |
WGK Germany | 3 |